Sign In
Buy AMGN
$345.60
+7.38 (+2.18%)
At Close: Jun 04, 2026
Amgen Inc. (NASDAQ:AMGN) Holdings Cut by Panagora Asset Management Inc.
07:14am, Monday, 20'th May 2024
Panagora Asset Management Inc. decreased its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.1% in the fourth quarter, according to the company in its most recent disclosure wi
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
05:15pm, Sunday, 19'th May 2024
Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels THOUSAND OAKS, Calif. , May 19, 2024 /PRNews
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
06:15am, Sunday, 19'th May 2024
Eli Lilly is generating billions of dollars thanks to its weight loss drugs -- and demand is outpacing supply. Rivals are hoping to carve out share in this high-growth market; Amgen was the latest to
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
12:51pm, Friday, 17'th May 2024
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
11:06am, Friday, 17'th May 2024
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this s
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
08:24am, Friday, 17'th May 2024
Wegovy and Zepbound are two of the hottest GLP-1 drugs available on the market right now. The field, however, could become more crowded as more companies develop rival treatments.
Amgen gets FDA approval for small-cell lung-cancer treatment
08:21pm, Thursday, 16'th May 2024
Amgen AMGN, -0.65% on Thursday received approval from U.S. regulators for its drug to treat a form of late-stage lung-cancer.
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall
FDA approves Amgen's treatment for most deadly form of lung cancer
03:57pm, Thursday, 16'th May 2024
The FDA cleared the Amgen drug, called Imdelltra, as a treatment for patients with advanced small-cell lung cancer.
US FDA approves Amgen drug for small cell lung cancer, Bloomberg reports
03:23pm, Thursday, 16'th May 2024
The U.S. Food and Drug Administration has granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for treating adults with advanced small cell lung cancer that has worsened despit
The Best Dividend Stocks For A Dovish Fed
10:29am, Thursday, 16'th May 2024
Remember when the Federal Reserve stopped printing money for a few months? It didn't go well.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
10:06am, Thursday, 16'th May 2024
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
06:45pm, Wednesday, 15'th May 2024
THOUSAND OAKS, Calif. , May 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m.
Trade Tracker: Joe Terranova buys Amgen and Merck
01:03pm, Wednesday, 15'th May 2024
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest buys
Amgen Inc. (AMGN) BofA Securities 2024 Health Care Conference (Transcript)
04:43pm, Tuesday, 14'th May 2024
Amgen Inc. (NASDAQ:AMGN ) BofA Securities 2024 Health Care Conference May 14, 2024 ET Company Participants Peter Griffith - EVP & CFO James Bradner - EVP, Research and Development & Chief Scientific O
